No. Analytical methods should be capable and stable. For most lab analyses, reprocessing
data should not be regularly needed. If chromatography is reprocessed, written
procedures must be established and followed and each result retained for review (see §§
211.160(a), 211.160(b), 211.165(c), 211.194(a)(4), and 212.60(a)). FDA requires
complete data in laboratory records, which includes raw data, graphs, charts, and spectra
from laboratory instruments (§§ 211.194(a) and 212.60(g)(3)).